Signatera™ changes the paradigm by expanding the adjuvant decision window, with up to 7 tests in the first year post-surgery, enabling effective initiation of treatment only after a positive test ...

To tailor cancer therapies to individual patients, Moderna, BioNTech and other companies are rethinking how they optimize manufacturing schedules and resources. In battling the COVID-19 pandemic, ...